Navigation Links
Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
Date:2/8/2011

HAYWARD, Calif., Feb. 8, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced that it has appointed Lawrence Rosania to the position of Vice President of Global Regulatory Affairs and Compliance. Mr. Rosania will be responsible for developing global regulatory strategies and managing all aspects of regulatory affairs.

"Larry's expertise in biologics and large molecule manufacturing is particularly valuable to Anthera as we consider a number of Phase 3 clinical options for A-623," said Paul F. Truex, Anthera's President and Chief Executive Officer. "A-623 represents a unique autoimmune platform and as we progress our own fermentation and manufacturing campaigns it will be imperative to have this depth of experience around the table.  We look forward to Larry's guidance in advancing our entire pipeline of products towards commercialization."

Prior to joining Anthera, Mr. Rosania served in a variety of senior-level consultant roles at The Weinberg Group, Quintiles Transnational, and as an independent consultant for the last 12 years. Prior to that, he served as Vice President of Regulatory Affairs and Compliance at LXR Biotechnology, Elan Pharmaceuticals and Athena Neurosciences, where he led the filings of two of their biologics, MyoBloc® (rimabotulinumtoxin B) for a Cervical Dystonia indication and Tysabri® (natalizumab) for a Multiple Sclerosis indication. Before relocating to the Bay Area in 1996, he had worked in various senior-level positions in R&D drug development, CMC, Regulatory Affairs and GXP Quality/Compliance at Novo-Nordisk, Bristol-Myers Squibb and E.R. Squibb & Sons, Inc. in Princeton, New Jersey. At Novo Nordisk, Mr. Rosania developed and implemented the US regulatory
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
(Date:7/23/2014)... -- When it comes to welcoming our new robot overlords, InformationWeek ... the red carpet. Healthcare is one of the ... into our human sphere. With healthcare concerns top of mind ... apply new technologies to help with old problems. That,s where ... expected to increase from $1.7 billion now to $3.7 billion ...
(Date:7/23/2014)... 2014  Researchers from the North American Menopause Society ... calcium levels too high, 1 putting women at ... Women close to menopause are commonly told to ... diseases such as osteoporosis, to which they are particularly ... how much calcium they typically get through their food ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Women Taking Too Much Calcium Create Health Risk 2
... announces that a new market research report is ... Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and ... http://www.reportlinker.com/p0479828/Juvenile-Rheumatoid-Arthritis-JRA-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Juvenile Rheumatoid Arthritis (JRA) ... 2017 Summary ...
... announces that a new market research report is ... Cancer Therapy Area Pipeline Report ... Therapy Area Pipeline Report contains detailed information on ... insight into the pipeline status of pancreatic cancer ...
Cached Medicine Technology:Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Pancreatic Cancer Therapy Area Pipeline Report 2Reportlinker Adds Pancreatic Cancer Therapy Area Pipeline Report 3
(Date:7/23/2014)... and young adults living near Sellafield or Dounreay since ... developing cancer according to research published in the ... from the Childhood Cancer Research Group at the University ... between 1963 and 2006 among those who were under ... No difference was found in cancer incidence from 1991-2006 ...
(Date:7/23/2014)... 2014 A new study has uncovered ... ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive hysterectomies can ... woman’s body, Bernstein Liebhard LLP reports. The research, which ... the American Medical Association, looked at 36,000 women who ... U.S. hospitals from 2006 to 2012. Ninety-nine of the ...
(Date:7/23/2014)... patients if a suspicious skin lesion is painful or ... likely to be cancerous, according to a new study ... of Dermatology at Temple University School of Medicine. , ... on July 23, 2014, found that nearly 36. 9 ... while 28.2 percent involve pain. Non-melanoma skin cancers ...
(Date:7/23/2014)... -- Painful or itchy skin lesions could be a ... sometimes have multiple lesions that are suspicious looking, and ... concerns for non-melanoma skin cancers," study author Dr. Gil ... Medicine, said in a Temple University Health System news ... 268 patients who were confirmed to have skin cancer ...
(Date:7/23/2014)... Rich Dad® Education, a leader in financial education, is ... to support Habit for Humanity of Lee and Hendry Counties. ... be donated to Habitat for Humanity. Additionally, all the items ... Habitat for Humanity ReStore thrift store located at 31 Willis ... the highlights of the yard sale was a visit from ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2
... its smoking ban to entertainment outlets including pubs, nightclubs ... cut tobacco-related diseases. ,The ban will ... city-state which already has some of the toughest anti-smoking ... restrict smoking in entertainment outlets is a natural extension ...
... opportunity for superstition and marketing to come together: starry-eyed couples ... Earth concerts as well as the proclamation of the world's ... 7 has a magic sacred side and the reputation of ... bring an extra dose of good fortune. ,"Number ...
... Brahmachari and Dr. MRS Rao will be jointly awarded the ... 2005 for their outstanding contribution in the field of bio-medical ... one lakh. ,Besides, the Indian Council of Medical ... country to be honoured for their outstanding contributions in research ...
... prospective study suggests that ovarian germ cell tumour ... may retain their menstrual function and reproductive ... the Journal of Clinical Oncology, also found that ... more likely than their healthy counterparts to be ...
... a cure for smelly and pongy feet - special socks made ... eco-friendly sock to go on general sale, and experts have forecasted ... to take place in the world of clothing. ... of the silky material, which is softer, more durable and absorbent ...
... a slew of studies have highlighted the adverse effects of ... hours of gaming can actually be good for children. ... competing against each other give children a chance to learn ... and other races. ,The study by researchers from ...
Cached Medicine News:Health News:Singapore Extends Smoking Ban to Pubs, Nightclubs 2Health News:A Lucky Number? 7/7/07 2Health News:A Lucky Number? 7/7/07 3Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 2Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 3Health News:Exposure to Computer Games can Be 'good' for Kids, Says New Study 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: